Periostin was thus recently used as a biomarker in a proof-of-concept study in patients with SSc to assess the response to Romilkimab therapy (a monoclonal bispecific antibody against IL-4/IL-13), showing a greater trend of reduction compared to placebo [24]. The gene discussed is IL4; the disease is systemic sclerosis.